Target intelligence / Profile preview

Interleukin-2 receptor subunit beta–cytokine receptor common gamma chain heterodimer (IL-2Rβγ) (IL-2Rβγ)

Target
IL-2Rβγ
Molecular classification
Type I cytokine receptor, Heterodimeric receptor, Receptor, Cytokine receptor
01

Overview

The Interleukin-2 receptor subunit beta–cytokine receptor common gamma chain heterodimer is a signaling complex composed of the IL-2Rβ (CD122) and γc (CD132) subunits (UniProt P14784, P31785). This heterodimer serves as the intermediate-affinity receptor for interleukin-2 (IL-2) and is the essential signaling component for interleukin-15 (IL-15) (PubMed: 22391154). It is constitutively expressed on memory CD8+ T cells and natural killer (NK) cells, whereas the high-affinity trimeric receptor (which includes IL-2Rα/CD25) is primarily found on regulatory T cells (Tregs) (PubMed: 29924973). Upon ligand binding, the heterodimer recruits Janus kinases JAK1 and JAK3 to initiate the STAT5, PI3K/Akt, and MAPK signaling pathways, which are critical for lymphocyte survival and effector function (PubMed: 31515344). In oncology, this complex is a major target for biased IL-2 agonists, such as bempegaldesleukin, designed to selectively activate CD8+ T and NK cells while avoiding the activation of immunosuppressive Tregs (PubMed: 31515344). Therapeutic modulation of this receptor complex is also explored in autoimmune diseases and chronic infections to fine-tune the balance of the immune response.

Other names
CD122/CD132 complexIntermediate-affinity IL-2 receptorIL-2Rβ/γcIL-15 receptor signaling complexIL-2Rβγ
02

Mechanism of action

Agonism of the IL-2/IL-15 signaling pathway via JAK/STAT activation; selective stimulation of effector T cells and NK cells.

03

Biological functions

Signal transductionImmune responseCell proliferationT cell activationNK cell activationApoptosis
04

Disease associations

CancerAutoimmune diseaseInfectionInflammation
05

Safety considerations

Vascular leak syndromeCytokine release syndromeHypotensionPulmonary edemaPyrexiaEosinophilia
06

Interacting drugs

Aldesleukin

7 more in the full profile.

07

Biomarkers

STAT5 phosphorylationCD8+ T cell expansionNK cell expansionCD8+/Treg ratioSoluble CD122

Beyond the preview

Go deeper on Interleukin-2 receptor subunit beta–cytokine receptor common gamma chain heterodimer (IL-2Rβγ) (IL-2Rβγ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-2 receptor subunit beta–cytokine receptor common gamma chain heterodimer (IL-2Rβγ) (IL-2Rβγ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call